Skip to main content
NCBI home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2026 Feb 1.
Published in final edited form as: Environ Res. 2024 Dec 5;266:120556. doi: 10.1016/j.envres.2024.120556

Associations between Per- and Polyfluoroalkyl Substances (PFAS) and Female Sexual Function in a Preconception Cohort

Samantha Schildroth 1,*,+, Julia Bond 1,*, Amelia K Wesselink 1, Jasmine Abrams 2, Antonia M Calafat 3, Julianne Cook Botelho 3, Katharine O White 4, Ganesa Wegienka 5, Elizabeth E Hatch 1, Lauren A Wise 1
PMCID: PMC11826513  NIHMSID: NIHMS2041255  PMID: 39644984

Abstract

Background:

Female sexual function is important for sexual well-being, general health, fertility, and relationship satisfaction. Distressing impairments in sexual function, clinically recognized as female sexual dysfunction (FSD), can manifest as issues with interest/desire, arousal, orgasm, and pain during vaginal penetration. Some evidence suggests that exposure to endocrine-disrupting chemicals may adversely affect female sexual function, but associations for per- and polyfluoroalkyl substances (PFAS) have not been previously evaluated.

Objective:

We investigated associations between serum PFAS concentrations and female sexual function among U.S. pregnancy planners.

Methods:

We used cross-sectional data from participants from Pregnancy Study Online (PRESTO), a prospective preconception cohort study. Participants reported sexual function at baseline on two validated measures: a modified version of the Female Sexual Function Index-6 (FSFI-6) and Female Sexual Distress Scale (FSDS). We quantified PFAS serum concentrations in samples collected in the preconception period (i.e., at baseline) using solid phase extraction-high performance liquid chromatography-isotope-dilution-mass spectrometry. Participants reported sociodemographic information on structured baseline questionnaires. We included 78 participants with complete PFAS and sexual function data and fit multivariable linear regression models to estimate mean differences in FSFI-6 scores (β) or percent differences (%) in FSDS scores per interquartile range (IQR) increase in PFAS concentrations, adjusting for age, annual household income, years of education, parity, and body mass index. We further investigated effect measure modification by parity (parous vs. nulliparous) in stratified models.

Results:

An IQR increase in perfluorohexanesulfonic acid was associated with a 1.0-point decrease (95% CI=−1.8, −0.1) in reported FSFI-6 scores, reflecting poorer sexual function. PFAS were consistently associated with lower FSFI-6 scores among parous participants. PFAS were also associated, though imprecisely, with greater sexual distress.

Conclusion:

Some PFAS were associated with poorer sexual function among parous U.S. pregnancy planners, but future studies are needed to clarify the extent to which PFAS influences female sexual health.

Keywords: PFAS, EDCs, sexual health, women, reproductive health

1. INTRODUCTION

Female sexual function, the ability to participate in and enjoy sexual activity, is important for female sexual well-being, fertility, relationship satisfaction, and general health (Diamond and Huebner, 2012; Flynn et al., 2016; Gianotten et al., 2021; Loy et al., 2021). The etiology of female sexual dysfunction (FSD), which can manifest as distressing issues with sexual desire/interest, arousal, orgasm, and pain during sexual activity and affects ~40% of premenopausal individuals (American Psychiatric Association, 2013; McCool et al., 2016; Parish et al., 2021), has not been fully characterized. Some studies indicate that exposure to endocrine-disrupting chemicals (EDCs) (i.e., phthalates) may deleteriously affect sexual function (Barrett et al., 2014; Kolena et al., 2024). EDCs are defined by their ability to dysregulate hormonal functions important for reproductive health (Ahn and Jeung, 2023; Diamanti-Kandarakis et al., 2009). Although multiple studies have been devoted to understanding the role of EDCs, including per- and polyfluoroalkyl substances (PFAS), on adverse reproductive (e.g., uterine fibroids, endometriosis, polycystic ovarian syndrome) and perinatal (e.g., birthweight, miscarriage, preterm birth, breastfeeding) outcomes (Ahn and Jeung, 2023; Bariani et al., 2020; Criswell et al., 2020; Huang et al., 2017; Jensen et al., 2015; Katz et al., 2016; Peterson et al., 2022; Rickard et al., 2022; Upson et al., 2013; Wesselink et al., 2021; Wolff et al., 2008; Yu et al., 2022; Zhang et al., 2021), female sexual function remains an understudied outcome in the environmental health field.

PFAS are a class of EDCs characterized by strong carbon-fluorine bonds that make them highly resistant to environmental degradation (Fenton et al., 2021). Individuals can be exposed to PFAS through diet, drinking water consumption, and from PFAS uses in industrial/military applications (e.g., firefighting foams) and consumer goods (e.g., food packaging, stain- and water-resistant textiles, personal care products) (Glüge et al., 2020; Smalling et al., 2023). In the U.S., human exposure to PFAS is widespread; it is estimated that >97% of Americans have detectable concentrations of PFAS in their blood, including legacy PFAS that have been banned or phased out given their environmental and biological persistence (Brennan et al., 2021; U.S. CDC, 2023). PFAS, like other EDCs, have documented hormonal effects in the body and have been associated with altered circulating levels of reproductive hormones that modulate female sexual function (e.g., lower estradiol, lower progesterone, and higher testosterone levels) (Barrett et al., 2015a; Harlow et al., 2021; Heffernan et al., 2018).

Because of their known endocrine-disrupting properties, it has been hypothesized that exposure to EDCs may adversely affect female sexual function. Of note, PFAS may deleteriously affect female sexual health by interfering with hormones (e.g., estradiol, progesterone) and inducing neurotoxicity in regions of the brain that mediate aspects of female sexual function, including vulvar blood flow, vaginal lubrication, and pelvic floor contractility (Azadzoi and Siroky, 2010; Brown-Leung and Cannon, 2022; Calabrò et al., 2019; Dennerstein et al., 2007; Elaine Waetjen et al., 2018; Salgado et al., 2016; Starnes et al., 2022a). To date, only two previous epidemiological studies have investigated associations of EDCs (phthalates) with female sexual health in U.S. pregnant individuals (n=360) or Slovakian university students (n=68) (Barrett et al., 2014; Kolena et al., 2024). Both studies reported associations between higher urinary biomarker concentrations of certain phthalates (e.g., di-(2-ethylhexyl) phthalate) and poorer sexual function, defined as issues with sexual desire, vaginal dryness, or poorer scores on a derived sexuality score (Barrett et al., 2014; Kolena et al., 2024). Despite study limitations, such as use of non-validated measures of sexual function, these studies support the hypothesis that EDC exposure can affect female sexual function. However, no previous study has investigated associations between PFAS exposure and female sexual function, despite their documented toxicological effects on female reproductive systems and pervasiveness of human exposure (Barrett et al., 2015a; Harlow et al., 2021; U.S. CDC, 2023).

The aim of the current study was to assess associations between preconception serum PFAS concentrations and female sexual function on two validated measures (Female Sexual Function Index-6 and Female Sexual Distress Scale) in a cohort of North American pregnancy planners.

2. METHODS

2.1. Study Population

We used cross-sectional data from Pregnancy Study Online (PRESTO), a North American prospective preconception cohort study. Female participants were eligible if they were 21–45 years and trying to conceive without the use of fertility treatments. The Boston University Medical Center (BUMC) Institutional Review Board approved study protocols. Involvement of the Centers for Disease Control and Prevention (CDC) did not constitute human subjects research.

2.2. Biomarker Collection and Measurement

We invited participants who lived or worked in the Boston and Detroit metropolitan areas to visit our clinics at BUMC or Henry Ford Health System to provide urine and blood samples within 2 weeks of enrollment (Koenig et al., 2022). We stored non-fasting serum samples at study clinics at −80°C and shipped samples to the U.S. CDC overnight on dry ice. Using solid phase extraction-high performance liquid chromatography-isotope-dilution-mass spectrometry, as described previously (Kato et al., 2018), CDC investigators measured serum concentrations of perfluorohexanesulfonic acid (PFHxS), linear and branch isomers of perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), perfluoroundecanoic acid (PFUnDA), and 2-(N-methyl-perfluorooctane sulfonamido) acetic acid (MeFOSAA). Four PFAS with detection frequencies ≥60% (limit of detection [LOD]=0.1 ng/mL) were included in the analysis: PFHxS, PFOS, PFOA, and PFNA. PFOS and PFOA reflected summed concentrations of their respective linear and branched isomers. There were few concentrations <LOD (PFHxS=3, PFOS=1, PFOA=1, PFNA=5); concentrations <LOD were imputed as the LOD/2 (Hornung and Reed, 1990). Most (n=40) serum samples were collected in 2023; the remaining samples were collected in 2016 (n=9), 2020 (n=18), or 2021 (n=11).

2.3. Female Sexual Health

We invited participants to complete an optional sexual health questionnaire 30 days after enrollment. Sixty percent of participants completed the optional survey, and non-participation was not appreciably associated with key demographic and clinical factors (Bond et al., 2022). We used a modified version of the 6-item Female Sexual Function Index (FSFI-6) (Isidori et al., 2010), which is an abbreviated version of the Female Sexual Function Index (Rosen et al., 2000). The Female Sexual Function Index has been used for over 20 years to identify female sexual dysfunction both in clinical practice and epidemiologic research (Meston et al., 2020). It uses 19 questions to assesses self-reported function over the past 4 weeks on six different domains of sexual function: perceived levels of sexual desire, arousal, and satisfaction, orgasm frequency, degree of vaginal lubrication, and occurrence of painful intercourse. Participants respond to questions using a Likert scale, with 1 indicating low function and 5 high function. Scores are summed, and there are established cut points that have been demonstrated to be highly sensitive and specific for clinically-confirmed female sexual dysfunction (Meston et al., 2020; Rosen et al., 2000). The abbreviated FSFI-6 uses one question for each of the 6 domains of sexual function, and also has an established cut point that has high sensitivity (0.93) and specificity (0.94) for clinically-confirmed female sexual dysfunction. The scale also has high internal reliability, with a Cronbach’s alpha of 0.789 (Isidori et al., 2010). We modified the original FSFI-6, replacing a question about vaginal lubrication frequency with a question about difficulty achieving vaginal lubrication from the full Female Sexual Function Index (Rosen et al., 2000). Responses to the new question, which we perceived as having higher specificity in capturing true sexual function issues, were highly correlated (r=0.79) with responses to the original question (Bond et al., 2024). We summed responses to the modified FSFI-6 were and calculated summed scores, with lower scores reflecting poorer function (possible range=2–30; sample range=2–29). The Cronbach’s alpha within our sample was 0.736.

In secondary analyses, we used the Female Sexual Distress Scale (FSDS), a validated 12-item scale, to assess distressing feelings about sexual function (Derogatis et al., 2011). This scale captures the degree of negative feelings related to a respondent’s sex life (e.g., embarrassment, shame, frustration) using Likert responses scored from 0 (no distress) to 4 (high distress). The scale is typically used to create a binary variable indicative of clinically-relevant distress related to sexual function, using a validated cut point. In validation studies, Cronbach’s alpha ranged from 0.86–0.93 (Derogatis et al., 2011). Distress related to sexual functioning, specifically negative feelings about one’s sex life, is necessary for a diagnosis of female sexual dysfunction (American Psychiatric Association, 2013) but is not captured by the FSFI-6. Thus, use of a validated questionnaire assessing distress is recommended in combination with the Female Sexual Function Index (Meston et al., 2020). We summed scores for each question, with higher scores indicative of more distress (possible range=0–48; range in PRESTO=0–36). Cronbach’s alpha within our sample was 0.94.

2.4. Covariates

Participants reported socioeconomic, demographic, reproductive history, and anthropometric data on a baseline questionnaire. Covariates included age (<25–29 years, 30–34 years, ≥35 years), annual household income (<$50,000-$99,000, $100,000-$149,000, ≥$150,000), educational attainment (<college degree, college degree, graduate school), parity (parous vs. nulliparous), and body mass index (BMI, kg/m2).

2.5. Statistical Analysis

The current analysis included 78 participants with complete PFAS biomarker and sexual health data. We first evaluated distributions and calculated summary statistics (medians, 25th-75th percentiles, percentages [%]) for all variables and estimated Spearman correlation coefficients between the PFAS. We assessed linearity of PFAS-FSFI score and PFAS-FSDS score associations using Generalized Additive Models (GAMs); there was no evidence of non-linear associations, and PFAS were modeled continuously in subsequent regression models.

Using a directed acyclic graph informed by the literature, we selected age, household income, educational attainment, parity, and BMI for inclusion in all statistical models (Berg et al., 2014; DeLuca et al., 2023; McCool-Myers et al., 2018; Park et al., 2019; Sagiv et al., 2015; Wise et al., 2021).

We fit multivariable linear regression models to estimate mean differences (with 95% confidence intervals [CIs]) in FSFI-6 scores per interquartile range (IQR) increase in PFAS concentrations, adjusting for hypothesized confounders. We further fit linear regression models in datasets stratified by parity (parous vs. nulliparous) to evaluate potential effect measure modification by parity because 1) menstruation, pregnancy, and breastfeeding are important elimination routes for PFAS (Kang et al., 2021; Mondal et al., 2014; Park et al., 2019; Sagiv et al., 2015; Upson et al., 2022; Wise et al., 2021), and 2) parity adversely affects aspects of female sexual health (Botros et al., 2006; McCool-Myers et al., 2018). We included calendar year at serum collection as a covariate in sensitivity analyses to adjust for potential time trends in PFAS concentrations.

In secondary analyses, we fit multivariable linear regression models to estimate associations between an IQR increase in serum PFAS concentrations and log-transformed FSDS scores, adjusting for hypothesized confounders, among participants who completed the FSDS (n=74). We back-transformed beta coefficients (with 95% CIs) as percent differences in FSFD scores.

3. RESULTS

At baseline, most participants were aged 30–34 years (50.0%), had household incomes ≥$100,000 (78.2%), and had graduate degrees (67.9%; Table 1). Notably, all participants in the analytic sample had attained a college degree. The median (25th-75th %) BMI was 23.9 (22.0–28.2) kg/m2. Nulliparous participants tended to be younger and have higher household incomes, higher educational attainment, and lower BMIs compared with parous participants. Median (25th-75th percentile) scores for the FSFI-6 and FSDS were 22.5 (20.0–25.0) and 5.0 (2.0–12.0), respectively, and nulliparous participants tended to have scores indicative of lower function and higher distress (Table 1; see also Figure S1).

Table 1.

Baseline characteristics of PRESTO participants, 2016–2023 (n=78).

Median (25th, 75th %) or N (%)
Full sample (n=78) Parous (n=18) Nulliparous (n=60)
Sociodemographic and anthropometric variables
Age (years)
 <25–29
 30–34
 ≥35
22 (28.2%)
39 (50.0%)
17 (21.8%)
3 (16.7%)
9 (50.0%)
6 (33.3%)
19 (31.7%)
30 (50.0%)
11 (18.3%)
Household income
 <$50,000-$99,000
 $100,000-$149,000
 ≥$150,000
17 (21.8%)
24 (30.8%)
37 (47.4%)
7 (38.9%)
7 (38.9%)
4 (22.2%)
10 (16.7%)
17 (28.3%)
33 (55.0%)
Educational attainment
 Some college/college degree
 Graduate school
25 (32.1%)
53 (67.9%)
8 (44.4%)
10 (55.6%)
17 (28.3%)
43 (71.7%)
BMI (kg/m2) 23.9 (22.0, 28.2) 25.5 (23.3, 32.4) 23.4 (21.3, 27.1)
Summed FSFI-6 scores 22.5 (20.0, 25.0) 23.5 (22.0, 25.0) 22.0 (19.8, 25.0)
Summed FSDS scores (n=74; parous n=18, nulliparous n=56) 5.0 (2.0, 12.0) 2.5 (0.0, 11.5) 5.0 (2.0, 12.0)
PFAS (ng/mL)
PFHxS 0.7 (0.4, 1.2) 0.4 (0.3, 0.5) 0.8 (0.5, 1.3)
PFOS 1.9 (1.2, 2.8) 1.5 (1.3, 1.8) 2.2 (1.4, 3.0)
PFOA 1.1 (0.8, 1.7) 0.5 (0.3, 0.8) 1.4 (1.0, 1.8)
PFNA 0.3 (0.2, 0.4) 0.2 (0.1, 0.3) 0.3 (0.2, 0.5)
Open in a new tab

Median (25th-75th percentile) serum PFAS concentrations ranged from 0.3 ng/mL (PFNA; 0.2–0.4 ng/mL) to 1.9 ng/mL (PFOS; 1.2–2.8 ng/mL; Table 1). PFAS concentrations were consistently higher among nulliparous participants. Spearman correlation coefficients between the PFAS ranged from 0.56 (PFHxS-PFNA) to 0.82 (PFOS-PFNA).

An IQR increase in serum PFHxS concentrations was associated with a 1.0-point decrease (95% CI=−1.8, −0.1) in modified FSFI-6 scores (Figure 1). Higher serum PFAS concentrations were consistently associated, though imprecisely, with lower modified FSFI-6 scores among parous participants: an IQR increase in PFHxS, PFOS, PFOA, and PFNA was associated with a 3.2-point (95% CI=−6.2, −0.1), 4.4-point (95% CI=−7.3, −1.6), 2.6-point (95% CI=−7.0, 1.9), and 3.7-point (95% CI=−6.6, −0.9) decrease in modified FSFI-6 scores (Figure 1), respectively. Associations were null among nulliparous participants, except for PFHxS (β=−0.9; 95% CI=−1.9, 0.0). Additional adjustment for calendar year at serum collection did not materially affect our primary findings because calendar year was not a strong predictor of sexual function (Table S1).

Figure 1.

Figure 1.

Open in a new tab

Associaons (95% CI) between an IQR increase in serum PFAS concentraons and FSFI-6 scores for A) the full sample (n=78), B) parous parcipants (n=18), and C) nulliparous parcipants (n=60) in Pregnancy Study Online. Beta coefficients reflect the mean difference in FSFI-6 scores.

1Models are adjusted for age, annual household income, years of educaon, parity, and BMI.

In secondary analyses, higher serum PFAS concentrations were consistently associated with greater sexual distress, operationalized using continuous FSFD scores, though these associations were imprecise (Figure 2). Notably, an IQR increase in PFHxS and PFOS was associated with a 50.3% (95% CI=−18.2%, 176.0%) and 53.9% (95% CI=−18.4%, 190.5%) increase in FSFD scores, respectively, consistent with findings from the FSFI-6.

Figure 2.

Figure 2.

Open in a new tab

Associaons (95% CI) between an IQR increase in serum PFAS concentraons and FSDS scores in Pregnancy Study Online (n=74). Beta coefficients reflect the percent (%) difference in FSDS scores.

1Models are adjusted for age, annual household income, years of educaon, parity, and BMI.

4. DISCUSSION

In a cohort of U.S. pregnancy planners, higher preconception serum concentrations of some PFAS were associated with poorer self-reported female sexual function, assessed using a modified version of the FSFI-6 (Isidori et al., 2010), and greater sexual distress, evaluated using the FSFD (Derogatis et al., 2011). Associations were consistently stronger, albeit also more imprecise, among parous participants compared with nulliparous participants. Although limited by the sample size, our findings nonetheless support the hypothesis that PFAS exposure may affect sexual function in reproductive-aged females.

To our knowledge, this is the first study investigating associations between PFAS and female sexual function. Our findings are generally consistent with two previous studies that evaluated phthalates, another EDC class, and female sexual health in U.S. pregnant individuals (n=360) and Slovakian university students (n=68). Notably, both studies reported associations between higher urinary biomarker concentrations of certain phthalates, including di-(2-ethylhexyl) phthalate, and poorer sexual function (i.e., vaginal dryness, issues with sexual desire) (Barrett et al., 2014; Kolena et al., 2024). Like PFAS (Barrett et al., 2015a; Harlow et al., 2021), phthalates can affect hormonal systems and have been associated with altered levels of reproductive hormones important for sexual function (Chiang et al., 2020; Deng et al., 2019; Li et al., 2012; Liu et al., 2014; Pfaus, 2009; Reinsberg et al., 2009; Salonia et al., 2010; Svechnikov et al., 2010; Treinen et al., 1990; Zhu et al., 2022). Together with the current findings, these studies support the hypothesis that exposure to EDCs may adversely affect female sexual function.

Our findings are further supported by toxicological data. PFAS have established neurotoxic mechanisms that may affect multiple aspects of sexual function (desire, arousal, orgasm, and pain). For example, PFAS can affect neurotransmission by dysregulating Ca2+ ion signaling, altering levels of neurotransmitter or receptor levels, and inducing oxidative stress, leading to poorer functional connectivity, in regions of the brain that modulate sexual function (e.g., hippocampus, amygdala, prefrontal cortex) (Brown-Leung and Cannon, 2022; Foguth et al., 2020; Pfaus, 2009; Salgado et al., 2016; Starnes et al., 2022b). PFAS exposure has also been shown to reduce circulating levels of kisspeptin (produced in the hypothalamus, hippocampus, and amygdala), a protein that stimulates gonadotropin releasing hormone and regulates sexual desire (Comninos et al., 2017; Starnes et al., 2022b). PFAS also have documented effects on hormonal systems and exposure can alter levels of hormones (estrogen, oxytocin, progesterone) that are important for maintaining pelvic floor musculature and supporting genital blood flow and vaginal lubrication, with implications for sexual desire, arousal, and pain (Azadzoi and Siroky, 2010; Calabrò et al., 2019; Dennerstein et al., 2007; Elaine Waetjen et al., 2018).

Interestingly, PFAS-FSFI associations were stronger among parous participants despite higher PFAS concentrations among nulliparous participants. Parity has been shown to act as an effect measure modifier on associations between PFAS and reproductive hormones (estrogen, progesterone) important for sexual function (Barrett et al., 2015b; Harlow et al., 2021; Salonia et al., 2010). For example, PFAS were more strongly associated with lower progesterone levels in nulliparous 25–35-year-old Norwegian females compared with parous females (Barrett et al., 2015b). Higher progesterone levels generally decrease female sexual desire (Cappelletti and Wallen, 2016), suggesting that reduced progesterone levels following PFAS exposure may increase desire, which may explain, in part, why we observed stronger negative associations between PFAS and sexual function among parous participants. Evidence is less clear for estrogen (Harlow et al., 2021), but these data nonetheless suggest that parity may be an important effect measure modifier of PFAS-reproductive hormone associations, and thus PFAS-sexual function associations. The potential role of reproductive hormones in PFAS-sexual health associations warrants additional research. In addition, stronger associations among parous participants may reflect effect measure modification by psychosocial or relationship factors that correlate with both parity and sexual health (Malina and Suwalska-Barancewicz, 2021; McCool-Myers et al., 2018). However, our stratified analysis was limited by its sample size and narrow concentration ranges for several PFAS (Table 1), and these findings should be corroborated in future studies.

Our study has many strengths, particularly that it is one of the first studies to consider female sexual function as a health endpoint in relation to any EDC exposure. We investigated this research question in an established preconception cohort that collected data on female sexual function using validated instruments (Derogatis et al., 2011; Isidori et al., 2010). We further assessed PFAS exposure objectively using serum PFAS concentrations, as a proxy for exposure, quantified in samples collected prior to pregnancy. However, as noted, our sample size was small, particularly for parous participants, limiting our statistical precision and ability to adjust for all potentially important confounders, especially prior breastfeeding duration and menstruation, which have been associated with PFAS concentrations (Wise et al., 2022) and sexual function (McCool-Myers et al., 2018). Our analysis was also cross-sectional. We therefore cannot rule out the possibility of residual confounding or clarify the directionality of associations in the current study. We also do not know the clinical significance of small changes in sexual function as assessed by the scales we used. These scales have established cut points to identify clinically-relevant FSD (Isidori et al., 2010) and distress (Derogatis et al., 2011), respectively, but we used these scales as continuous outcome variables because of limited sample size. Nonetheless, both of these scales are well established, having been used extensively in clinical and epidemiologic research into female sexual dysfunction and distress for over 20 years (Derogatis et al., 2011; Meston et al., 2020). Despite the noted influences of sexual function on quality of life, mental health, and relationship quality (Diamond and Huebner, 2012; Flynn et al., 2016; Gianotten et al., 2021), little research has evaluated the association between environmental toxicants and female sexual dysfunction. The dearth of research on this topic highlights a need for innovative research using established tools.

In conclusion, we reported inverse associations between serum PFAS concentrations and female sexual function, an understudied outcome in environmental health research. Female sexual function is important for overall quality of life, relationship satisfaction, and sexual wellbeing, and adverse effects of EDCs on sexual function therefore have implications for positive female sexual expression and overall health. Due to our limited sample and cross-sectional study design, additional studies with prospective designs and larger sample sizes are needed to support our findings.

Supplementary Material

1

HIGHLIGHTS.

  • Per- and polyfluoroalkyl substances (PFAS) are endocrine-disrupting chemicals (EDCs) that affect reproductive health.

  • Female sexual function is important for positive sexual expression and well-being.

  • Few studies have considered female sexual function in studies of EDCs exposure.

  • Serum PFAS concentrations were associated with poorer female sexual function among parous U.S. pregnancy planners.

  • PFAS exposure may affect female sexual health.

ACKNOWLEDGMENTS

This work was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01-HD086742) and the National Institute of Environmental Health Sciences (R01ES029951).

Abbreviations:

PFAS

per- and polyfluoroalkyl substances

EDCs

endocrine-disrupting chemicals

FSD

female sexual dysfunction

FSFI-6

Female Sexual Function Index-6

FSDS

Female Sexual Distress Scale

PRESTO

Pregnancy Study Online

PFHxS

perfluorohexanesulfonic acid

PFOS

perfluorooctanesulfonic acid

PFOA

perfluorooctanoic acid (PFOA)

PFNA

perfluorononanoic acid

Footnotes

The authors declare they have no conflicts of interest related to this work to disclose.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). The use of trade names is for identification only and does not imply endorsement by the CDC.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

DATA STATEMENT

The data used in this manuscript are confidential.

REFERENCES

  1. Ahn C, Jeung EB, 2023. Endocrine-Disrupting Chemicals and Disease Endpoints. Int J Mol Sci 24. 10.3390/IJMS24065342 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. American Psychiatric Association, 2013. Diagnostic and Statistical Manual of Mental Disorders, 5th ed, Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association. 10.1176/APPI.BOOKS.9780890425596 [DOI] [Google Scholar]
  3. Azadzoi KM, Siroky MB, 2010. Neurologic Factors in Female Sexual Function and Dysfunction. Korean J Urol 51, 443. 10.4111/KJU.2010.51.7.443 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bariani MV, Rangaswamy R, Siblini H, Yang Q, Al-Hendy A, Zota AR, 2020. The role of endocrine-disrupting chemicals in uterine fibroid pathogenesis. Curr Opin Endocrinol Diabetes Obes 27, 380–387. 10.1097/MED.0000000000000578 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Barrett ES, Chen C, Thurston SW, Haug LS, Sabaredzovic A, Fjeldheim FN, Frydenberg H, Lipson SF, Ellison PT, Thune I, 2015a. Perfluoroalkyl substances and ovarian hormone concentrations in naturally cycling women. Fertil Steril 103, 1261–1270.e3. 10.1016/J.FERTNSTERT.2015.02.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Barrett ES, Chen C, Thurston SW, Haug LS, Sabaredzovic A, Fjeldheim FN, Frydenberg H, Lipson SF, Ellison PT, Thune I, 2015b. Perfluoroalkyl substances (PFASs) and ovarian hormone concentrations in naturally cycling women. Fertil Steril 103, 1261. 10.1016/J.FERTNSTERT.2015.02.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Barrett ES, Parlett LE, Wang C, Drobnis EZ, Bruce Redmon J, Swan SH, 2014. Environmental exposure to di-2-ethylhexyl phthalate is associated with low interest in sexual activity in premenopausal women. Horm Behav 66, 787. 10.1016/J.YHBEH.2014.10.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Berg V, Nøst TH, Huber S, Rylander C, Hansen S, Veyhe AS, Fuskevåg OM, Odland JØ, Sandanger TM, 2014. Maternal serum concentrations of per- and polyfluoroalkyl substances and their predictors in years with reduced production and use. Environ Int 69, 58–66. 10.1016/j.envint.2014.04.010 [DOI] [PubMed] [Google Scholar]
  9. Bond JC, Abrams J, Wesselink AK, White KO, Rothman KJ, Wise LA, 2022. Predictors of Non-Response to a Sexual Health Survey in a North American Preconception Cohort Study. J Sex Med 19, 1707–1715. 10.1016/J.JSXM.2022.08.199 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bond JC, Heaton B, White KO, Abrams JA, Kuohung W, Fisher RR, Wesselink AK, Fox MP, Wise LA, 2024. Female sexual function and distress and time-to-pregnancy in a prospective preconception cohort. Am J Obstet Gynecol. 10.1016/J.AJOG.2024.09.117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Botros SM, Abramov Y, Miller JJR, Sand PK, Gandhi S, Nickolov A, Goldberg RP, 2006. Effect of parity on sexual function: an identical twin study. Obstetrics and gynecology 107, 765–770. 10.1097/01.AOG.0000207677.03235.76 [DOI] [PubMed] [Google Scholar]
  12. Brennan NM, Evans AT, Fritz MK, Peak SA, von Holst HE, 2021. Trends in the regulation of per-and polyfluoroalkyl substances (PFAS): A scoping review. Int J Environ Res Public Health 18, 10900. 10.3390/IJERPH182010900/S1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Brown-Leung JM, Cannon JR, 2022. Neurotransmission Targets of Per- and Polyfluoroalkyl Substance Neurotoxicity: Mechanisms and Potential Implications for Adverse Neurological Outcomes. Chem Res Toxicol 35, 1312–1333. 10.1021/ACS.CHEMRESTOX.2C00072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Calabrò RS, Cacciola A, Bruschetta D, Milardi D, Quattrini F, Sciarrone F, la Rosa G, Bramanti P, Anastasi G, 2019. Neuroanatomy and function of human sexual behavior: A neglected or unknown issue? Brain Behav 9. 10.1002/BRB3.1389 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cappelletti M, Wallen K, 2016. Increasing women’s sexual desire: The comparative effectiveness of estrogens and androgens. Horm Behav 78, 178. 10.1016/J.YHBEH.2015.11.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Chiang C, Lewis LR, Borkowski G, Flaws JA, 2020. Exposure to Di(2-ethylhexyl) Phthalate and Diisononyl Phthalate During Adulthood Disrupts Hormones and Ovarian Folliculogenesis Throughout the Prime Reproductive Life of the Mouse. Toxicol Appl Pharmacol 393, 114952. 10.1016/J.TAAP.2020.114952 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Comninos AN, Wall MB, Demetriou L, Shah AJ, Clarke SA, Narayanaswamy S, Nesbitt A, Izzi-Engbeaya C, Prague JK, Abbara A, Ratnasabapathy R, Salem V, Nijher GM, Jayasena CN, Tanner M, Bassett P, Mehta A, Rabiner EA, Hönigsperger C, Silva MR, Brandtzaeg OK, Lundanes E, Wilson SR, Brown RC, Thomas SA, Bloom SR, Dhillo WS, 2017. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest 127, 709–719. 10.1172/JCI89519 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Criswell R, Crawford KA, Bucinca H, Romano ME, 2020. Endocrine-Disrupting Chemicals and Breastfeeding Duration: A Review. Curr Opin Endocrinol Diabetes Obes 27, 388. 10.1097/MED.0000000000000577 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. DeLuca NM, Thomas K, Mullikin A, Slover R, Stanek LW, Pilant AN, Cohen Hubal EA, 2023. Geographic and demographic variability in serum PFAS concentrations for pregnant women in the United States. Journal of Exposure Science & Environmental Epidemiology 2023 33:5 33, 710–724. 10.1038/s41370-023-00520-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Deng T, Xie X, Duan J, Chen M, 2019. Di-(2-ethylhexyl) phthalate induced an increase in blood pressure via activation of ACE and inhibition of the bradykinin-NO pathway. Environ Pollut 247, 927–934. 10.1016/J.ENVPOL.2019.01.099 [DOI] [PubMed] [Google Scholar]
  21. Dennerstein L, Lehert P, Burger HG, Guthrie JR, 2007. New findings from non-linear longitudinal modelling of menopausal hormone changes. Hum Reprod Update 13, 551–557. 10.1093/HUMUPD/DMM022 [DOI] [PubMed] [Google Scholar]
  22. Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J, 2011. The Female Sexual Distress Scale (FSDS): Initial Validation of a Standardized Scale for Assessment of Sexually Related Personal Distress in Women. 28, 317–330. 10.1080/00926230290001448 [DOI] [PubMed] [Google Scholar]
  23. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, Zoeller RT, Gore AC, 2009. Endocrine-disrupting chemicals: An Endocrine Society scientific statement. Endocr Rev 30, 293–342. 10.1210/er.2009-0002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Diamond LM, Huebner DM, 2012. Is Good Sex Good for You? Rethinking Sexuality and Health. Soc Personal Psychol Compass 6, 54–69. 10.1111/J.1751-9004.2011.00408.X [DOI] [Google Scholar]
  25. Elaine Waetjen L, Crawford SL, Chang PY, Reed BD, Hess R, Avis NE, Harlow SD, Greendale GA, Dugan SA, Gold EB, 2018. Factors associated with developing vaginal dryness symptoms in women transitioning through menopause: a longitudinal study. Menopause 25, 1094. 10.1097/GME.0000000000001130 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Fenton SE, Ducatman A, Boobis A, DeWitt JC, Lau C, Ng C, Smith JS, Roberts SM, 2021. Per- and Polyfluoroalkyl Substance Toxicity and Human Health Review: Current State of Knowledge and Strategies for Informing Future Research. Environ Toxicol Chem 40, 606. 10.1002/ETC.4890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Flynn KE, Lin L, Bruner DW, Cyranowski JM, Hahn EA, Jeffery DD, Reese JB, Reeve BB, Shelby RA, Weinfurt KP, 2016. Sexual Satisfaction and the Importance of Sexual Health to Quality of Life Throughout the Life Course of U.S. Adults. J Sex Med 13, 1642–1650. 10.1016/J.JSXM.2016.08.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Foguth R, Sepúlveda MS, Cannon J, 2020. Per- and Polyfluoroalkyl Substances (PFAS) Neurotoxicity in Sentinel and Non-Traditional Laboratory Model Systems: Potential Utility in Predicting Adverse Outcomes in Human Health. Toxics 8. 10.3390/TOXICS8020042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Gianotten WL, Alley JC, Diamond LM, 2021. The Health Benefits of Sexual Expression. International Journal of Sexual Health 33, 478–493. 10.1080/19317611.2021.1966564 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Glüge J, Scheringer M, Cousins IT, Dewitt JC, Goldenman G, Herzke D, Lohmann R, Ng CA, Trier X, Wang Z, 2020. An overview of the uses of per- and polyfluoroalkyl substances (PFAS). Environ Sci Process Impacts 22, 2345. 10.1039/D0EM00291G [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Harlow SD, Hood MM, Ding N, Mukherjee B, Calafat AM, Randolph JF, Gold EB, Park SK, 2021. Per- and Polyfluoroalkyl Substances and Hormone Levels During the Menopausal Transition. J Clin Endocrinol Metab 106, e4427. 10.1210/CLINEM/DGAB476 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Heffernan AL, Cunningham TK, Drage DS, Aylward LL, Thompson K, Vijayasarathy S, Mueller JF, Atkin SL, Sathyapalan T, 2018. Perfluorinated alkyl acids in the serum and follicular fluid of UK women with and without polycystic ovarian syndrome undergoing fertility treatment and associations with hormonal and metabolic parameters. Int J Hyg Environ Health 221, 1068–1075. 10.1016/J.IJHEH.2018.07.009 [DOI] [PubMed] [Google Scholar]
  33. Hornung RW, Reed LD, 1990. Estimation of Average Concentration in the Presence of Nondetectable Values. Appl Occup Environ Hyg 5, 46–51. 10.1080/1047322X.1990.10389587 [DOI] [Google Scholar]
  34. Huang YF, Pan WC, Tsai YA, Chang CH, Chen PJ, Shao Y. shuan, Tsai MS, Hou JW, Lu C. (Alex), Chen ML, 2017. Concurrent exposures to nonylphenol, bisphenol A, phthalates, and organophosphate pesticides on birth outcomes: A cohort study in Taipei, Taiwan. Science of the Total Environment 607–608, 1126–1135. 10.1016/j.scitotenv.2017.07.092 [DOI] [PubMed] [Google Scholar]
  35. Isidori AM, Pozza C, Esposito K, Giugliano D, Morano S, Vignozzi L, Corona G, Lenzi A, Jannini EA, 2010. Original Research—Outcomes Assessment: Development and Validation of a 6-Item Version of the Female Sexual Function Index (FSFI) as a Diagnostic Tool for Female Sexual Dysfunction. J Sex Med 7, 1139–1146. 10.1111/J.1743-6109.2009.01635.X [DOI] [PubMed] [Google Scholar]
  36. Jensen TK, Andersen LB, Kyhl HB, Nielsen F, Christesen HT, Grandjean P, 2015. Association between Perfluorinated Compound Exposure and Miscarriage in Danish Pregnant Women. PLoS One 10, e0123496. 10.1371/JOURNAL.PONE.0123496 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Kang H, Kim HS, Yoon YS, Lee Jeongsun, Kho Y, Lee Jisun, Chang HJ, Cho YH, Kim YA, 2021. Placental transfer and composition of perfluoroalkyl substances (PFASs): A Korean birth panel of parent-infant triads. Toxics 9. 10.3390/TOXICS9070168/S1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Kato K, Kalathil A, Patel A, Ye X, Calafat A, 2018. Per- and polyfluoroalkyl substances and fluorinated alternatives in urine and serum by on-line solid phase extraction-liquid chromatography-tandem mass spectrometry. Chemosphere 209, 338–345. 10.1016/J.CHEMOSPHERE.2018.06.085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Katz TA, Yang Q, Treviño LS, Walker CL, Al-Hendy A, 2016. Endocrine-disrupting chemicals and uterine fibroids. Fertil Steril. 10.1016/j.fertnstert.2016.08.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Koenig MR, Wesselink AK, Kuriyama AS, Chaiyasarikul A, Hatch EE, Wise LA, 2022. Feasibility of mail-based biospecimen collection in an online preconception cohort study. Frontiers in Reproductive Health 4, 1052231. 10.3389/FRPH.2022.1052231/BIBTEX [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Kolena B, Hlisníková H, Nagyová M, Orendáčová K, Vondráková M, Petrovičová I, Mlynček M, Weiss P, Pfaus JG, 2024. Endocrine effect of phthalate metabolites and a butterfly effect of prenatal exposure to androgens on qualitative aspects of female sexual response- an initial survey. International Journal of Impotence Research 2024 1–9. 10.1038/s41443-024-00919-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Li N, Liu T, Zhou L, He J, Ye L, 2012. Di-(2-ethylhcxyl) phthalate reduces progesterone levels and induces apoptosis of ovarian granulosa cell in adult female ICR mice. Environ Toxicol Pharmacol 34, 869–875. 10.1016/J.ETAP.2012.08.013 [DOI] [PubMed] [Google Scholar]
  43. Liu T, Li N, Zhu J, Yu G, Guo K, Zhou L, Zheng D, Qu X, Huang J, Chen X, Wang S, Ye L, 2014. Effects of di-(2-ethylhexyl) phthalate on the hypothalamus-pituitary-ovarian axis in adult female rats. Reprod Toxicol 46, 141–147. 10.1016/J.REPROTOX.2014.03.006 [DOI] [PubMed] [Google Scholar]
  44. Loy SL, Ku CW, Cheung YB, Godfrey KM, Chong YS, Shek LPC, Tan KH, Yap FKP, Bernard JY, Chen H, Chan SY, Tan TY, Chan JKY, 2021. Fecundability in reproductive aged women at risk of sexual dysfunction and associated risk factors: a prospective preconception cohort study. BMC Pregnancy Childbirth 21, 1–13. 10.1186/S12884-021-03892-5/TABLES/3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Malina A, Suwalska-Barancewicz D, 2021. Comparison of Early-Stage Mothers and Childless Women Seeking Pregnancy: Experienced Stress, Resilience and Satisfaction with Relationship with the Partner. Int J Environ Res Public Health 18, 1–15. 10.3390/IJERPH18052543 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. McCool ME, Zuelke A, Theurich MA, Knuettel H, Ricci C, Apfelbacher C, 2016. Prevalence of Female Sexual Dysfunction Among Premenopausal Women: A Systematic Review and Meta-Analysis of Observational Studies. Sex Med Rev 4, 197–212. 10.1016/J.SXMR.2016.03.002 [DOI] [PubMed] [Google Scholar]
  47. McCool-Myers M, Theurich M, Zuelke A, Knuettel H, Apfelbacher C, 2018. Predictors of female sexual dysfunction: a systematic review and qualitative analysis through gender inequality paradigms. BMC Womens Health 18. 10.1186/S12905-018-0602-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Meston CM, Freihart BK, Handy AB, Kilimnik CD, Rosen RC, 2020. Scoring and Interpretation of the FSFI: What can be Learned From 20 Years of use? J Sex Med 17, 17–25. 10.1016/J.JSXM.2019.10.007 [DOI] [PubMed] [Google Scholar]
  49. Mondal D, Weldon RH, Armstrong BG, Gibson LJ, Lopez-Espinosa MJ, Shin HM, Fletcher T, 2014. Breastfeeding: A potential excretion route for mothers and implications for infant exposure to perfluoroalkyl acids. Environ Health Perspect 122, 187–192. 10.1289/EHP.1306613 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Parish SJ, Cottler-Casanova S, Clayton AH, McCabe MP, Coleman E, Reed GM, 2021. The Evolution of the Female Sexual Disorder/Dysfunction Definitions, Nomenclature, and Classifications: A Review of DSM, ICSM, ISSWSH, and ICD. Sex Med Rev 9, 36–56. 10.1016/J.SXMR.2020.05.001 [DOI] [PubMed] [Google Scholar]
  51. Park SK, Peng Q, Ding N, Mukherjee B, Harlow SD, 2019. Determinants of per- and polyfluoroalkyl substances (PFAS) in midlife women: Evidence of racial/ethnic and geographic differences in PFAS exposure. Environ Res 175, 186–199. 10.1016/J.ENVRES.2019.05.028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Peterson AK, Eckel SP, Habre R, Yang T, Faham D, Farzan SF, Grubbs BH, Kannan K, Robinson M, Lerner D, Al-Marayati LA, Walker DK, Grant EG, Bastain TM, Breton CV, 2022. Prenatal Perfluorooctanoic Acid (PFOA) Exposure Is Associated With Lower Infant Birthweight Within the MADRES Pregnancy Cohort. Frontiers in Epidemiology 2, 21. 10.3389/FEPID.2022.934715 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Pfaus JG, 2009. Pathways of Sexual Desire. J Sex Med 6, 1506–1533. 10.1111/J.1743-6109.2009.01309.X [DOI] [PubMed] [Google Scholar]
  54. Reinsberg J, Wegener-Toper P, van der Ven K, van der Ven H, Klingmueller D, 2009. Effect of mono-(2-ethylhexyl) phthalate on steroid production of human granulosa cells. Toxicol Appl Pharmacol 239, 116–123. 10.1016/J.TAAP.2009.05.022 [DOI] [PubMed] [Google Scholar]
  55. Rickard BP, Rizvi I, Fenton SE, 2022. Per- and poly-fluoroalkyl substances (PFAS) and female reproductive outcomes: PFAS elimination, endocrine-mediated effects, and disease. Toxicology 465, 153031. 10.1016/J.TOX.2021.153031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D’Agostino R, 2000. The Female Sexual Function Index (FSFI): A Multidimensional Self-Report Instrument for the Assessment of Female Sexual Function. J Sex Marital Ther 26, 191–205. 10.1080/009262300278597 [DOI] [PubMed] [Google Scholar]
  57. Sagiv SK, Rifas-Shiman SL, Webster TF, Mora AM, Harris MH, Calafat AM, Ye X, Gillman MW, Oken E, 2015. Sociodemographic and Perinatal Predictors of Early Pregnancy Per- and Polyfluoroalkyl Substance (PFAS) Concentrations. Environ Sci Technol 49, 11849–11858. 10.1021/acs.est.5b02489 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Salgado R, López-Doval S, Pereiro N, Lafuente A, 2016. Perfluorooctane sulfonate (PFOS) exposure could modify the dopaminergic system in several limbic brain regions. Toxicol Lett 240, 226–235. 10.1016/J.TOXLET.2015.10.023 [DOI] [PubMed] [Google Scholar]
  59. Salonia A, Giraldi A, Chivers ML, Georgiadis JR, Levin R, Maravilla KR, McCarthy MM, 2010. Physiology of Women’s Sexual Function: Basic Knowledge and New Findings. J Sex Med 7, 2637–2660. 10.1111/J.1743-6109.2010.01810.X [DOI] [PubMed] [Google Scholar]
  60. Smalling KL, Romanok KM, Bradley PM, Morriss MC, Gray JL, Kanagy LK, Gordon SE, Williams BM, Breitmeyer SE, Jones DK, DeCicco LA, Eagles-Smith CA, Wagner T, 2023. Per- and polyfluoroalkyl substances (PFAS) in United States tapwater: Comparison of underserved private-well and public-supply exposures and associated health implications. Environ Int 178. 10.1016/J.ENVINT.2023.108033 [DOI] [PubMed] [Google Scholar]
  61. Starnes HM, Rock KD, Jackson TW, Belcher SM, 2022a. A Critical Review and Meta-Analysis of Impacts of Per- and Polyfluorinated Substances on the Brain and Behavior. Frontiers in Toxicology 4. 10.3389/FTOX.2022.881584/FULL [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Starnes HM, Rock KD, Jackson TW, Belcher SM, 2022b. A Critical Review and Meta-Analysis of Impacts of Per- and Polyfluorinated Substances on the Brain and Behavior. Frontiers in Toxicology 4. 10.3389/FTOX.2022.881584/FULL [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Svechnikov K, Svechnikova I, Söder O, 2010. Gender-specific adverse effects of mono-ethylhexyl phthalate on steroidogenesis in immature granulosa cells and rat Leydig cell progenitors in vitro. Front Endocrinol (Lausanne) 2, 9681. 10.3389/FENDO.2011.00009/BIBTEX [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Treinen KA, Dodson WC, Heindel JJ, 1990. Inhibition of FSH-stimulated cAMP accumulation and progesterone production by mono(2-ethylhexyl) phthalate in rat granulosa cell cultures. Toxicol Appl Pharmacol 106, 334–340. 10.1016/0041-008X(90)90252-P [DOI] [PubMed] [Google Scholar]
  65. Upson K, Sathyanarayana S, Roos A.J. De, Thompson, Lou M, Scholes D, Dills R, Holt VL, 2013. Phthalates and risk of endometriosis. Environ Res 126, 91. 10.1016/J.ENVRES.2013.07.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Upson K, Shearston JA, Kioumourtzoglou MA, 2022. An Epidemiologic Review of Menstrual Blood Loss as an Excretion Route for Per- and Polyfluoroalkyl Substances. Curr Environ Health Rep 9, 29–37. 10.1007/S40572-022-00332-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. U.S. CDC, 2023. Fourth National Report on Human Exposure to Environmental Chemicals. [PubMed] [Google Scholar]
  68. Wesselink AK, Weuve J, Fruh V, Bethea TN, Claus Henn B, Harmon QE, Hauser R, Williams PL, Calafat AM, McClean M, Baird DD, Wise LA, 2021. Urinary concentrations of phenols, parabens, and triclocarban in relation to uterine leiomyomata incidence and growth. Fertil Steril 116, 1590–1600. 10.1016/J.FERTNSTERT.2021.07.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Wise LA, Wesselink AK, Schildroth S, Calafat AM, Bethea TN, Geller RJ, Coleman CM, Fruh V, Claus Henn B, Botelho JC, Harmon QE, Thirkill M, Wegienka GR, Baird DD, 2022. Correlates of plasma concentrations of per- and poly-fluoroalkyl substances among reproductive-aged Black women. Environ Res 203, 111860. 10.1016/J.ENVRES.2021.111860 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Wise LA, Wesselink AK, Schildroth S, Calafat AM, Bethea TN, Geller RJ, Coleman CM, Fruh V, Henn BC, Botelho JC, Harmon QE, Thirkill M, Wegienka GR, Baird DD, 2021. Correlates of plasma concentrations of per- and poly-fluoroalkyl substances among reproductive-aged Black women. Environ Res 203. 10.1016/J.ENVRES.2021.111860 [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Wolff MS, Engel SM, Berkowitz GS, Ye X, Silva MJ, Zhu C, Wetmur J, Calafat AM, 2008. Prenatal phenol and phthalate exposures and birth outcomes. Environ Health Perspect 116, 1092–1097. 10.1289/ehp.11007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Yu Y, Qin X-D, Bloom MS, Chu C, Dai X, Li Q, Chen Z-X, Kong M-L, Xie Y-Q, Meng W-J, Yang B-Y, Hu L-W, Zeng X-W, Zhao X-M, Zhou Y, Dong G-H, 2022. Associations of prenatal exposure to perfluoroalkyl substances with preterm birth: A family-based birth cohort study. Environ Res 214, 113803. 10.1016/J.ENVRES.2022.113803 [DOI] [PubMed] [Google Scholar]
  73. Zhang Y, Mustieles V, Williams PL, Wylie BJ, Souter I, Calafat AM, Demokritou M, Lee A, Vagios S, Hauser R, Messerlian C, 2021. Parental preconception exposure to phenol and phthalate mixtures and the risk of preterm birth. Environ Int 151, 106440. 10.1016/J.ENVINT.2021.106440 [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Zhu Y. duo, Han X, Wang Xin qi, Ge T. xi, Liu H, Fan L Li L, Su L. qin Wang, liang Xian, 2022. Effect of the phthalates exposure on sex steroid hormones in the US population. Ecotoxicol Environ Saf 231, 113203. 10.1016/J.ECOENV.2022.113203 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1
NIHMS2041255-supplement-1.docx (201KB, docx)

Data Availability Statement

The data used in this manuscript are confidential.

RESOURCES